William Blair Has Pessimistic Outlook of LRMR Q1 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Research analysts at William Blair decreased their Q1 2025 EPS estimates for Larimar Therapeutics in a research note issued on Monday, March 24th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($0.46) for the quarter, down from their previous estimate of ($0.35). The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. William Blair also issued estimates for Larimar Therapeutics’ Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.01) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.52) EPS and FY2026 earnings at ($2.07) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last announced its earnings results on Monday, March 24th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.16).

Several other equities analysts have also recently commented on LRMR. Guggenheim reissued a “buy” rating and set a $26.00 target price on shares of Larimar Therapeutics in a research note on Tuesday. Robert W. Baird lowered their price objective on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday. Truist Financial started coverage on Larimar Therapeutics in a research report on Wednesday, January 29th. They issued a “buy” rating and a $18.00 target price for the company. Finally, HC Wainwright increased their price target on Larimar Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday. Eleven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Larimar Therapeutics has a consensus rating of “Buy” and a consensus target price of $20.22.

Larimar Therapeutics Stock Down 2.1 %

Shares of NASDAQ LRMR opened at $2.35 on Thursday. The stock has a market cap of $149.95 million, a P/E ratio of -2.04 and a beta of 0.99. The firm’s 50-day simple moving average is $3.08 and its 200 day simple moving average is $5.12. Larimar Therapeutics has a fifty-two week low of $2.19 and a fifty-two week high of $11.20.

Institutional Investors Weigh In On Larimar Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of LRMR. Fi3 FINANCIAL ADVISORS LLC increased its stake in Larimar Therapeutics by 16.7% in the 4th quarter. Fi3 FINANCIAL ADVISORS LLC now owns 23,798 shares of the company’s stock worth $92,000 after purchasing an additional 3,411 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Larimar Therapeutics by 18.7% in the third quarter. JPMorgan Chase & Co. now owns 21,771 shares of the company’s stock worth $143,000 after buying an additional 3,425 shares during the period. Franklin Resources Inc. increased its position in shares of Larimar Therapeutics by 21.9% in the third quarter. Franklin Resources Inc. now owns 19,723 shares of the company’s stock worth $143,000 after acquiring an additional 3,549 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of Larimar Therapeutics by 12.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 35,525 shares of the company’s stock worth $137,000 after acquiring an additional 3,877 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Larimar Therapeutics by 8.1% during the fourth quarter. Bank of America Corp DE now owns 53,190 shares of the company’s stock valued at $206,000 after acquiring an additional 3,980 shares during the period. 91.92% of the stock is owned by institutional investors and hedge funds.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.